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1) Singapore General Hospital, 2) Tan Tock Seng Hospital and 3) National University Health System, Singapore, SingaporeAbstractNontuberculous mycobacteria infection is a growing global concern, but data from Asia are limited. This study aimed to describe the
distribution and antibiotic susceptibility proﬁles of rapidly growing mycobacterium (RGM) isolates in Singapore. Clinical RGM isolates
with antibiotic susceptibility tests performed between 2006 and 2011 were identiﬁed using microbiology laboratory databases and
minimum inhibitory concentrations of amikacin, cefoxitin, clarithromycin, ciproﬂoxacin, doxycycline, imipenem, linezolid, moxiﬂoxacin,
sulfamethoxazole or trimethoprim-sulfamethoxazole, tigecycline and tobramycin were recorded. Regression analysis was performed to
detect changes in antibiotic susceptibility patterns over time. A total of 427 isolates were included. Of these, 277 (65%) were from
respiratory specimens, 42 (10%) were related to skin and soft tissue infections and 36 (8%) were recovered from blood specimens. The
two most common species identiﬁed were Mycobacterium abscessus (73%) and Mycobacterium fortuitum group (22%), with amikacin and
clarithromycin being most active against the former, and quinolones and trimethoprim-sulfamethoxazole against the latter. Decreases in
susceptibility of M. abscessus to linezolid by 8.8% per year (p 0.001), M. fortuitum group to imipenem by 9.5% per year (p 0.023) and
clarithromycin by 4.7% per year (p 0.033) were observed. M. abscessus in respiratory specimens is the most common RGM identiﬁed in
Singapore. Antibiotic options for treatment of RGM infections are increasingly limited.
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E-mail: sarah.tang.s.l@sgh.com.sgIntroductionNontuberculous mycobacteria (NTM) are ubiquitous organisms
commonly found in the environment. Although they are
traditionally not considered a major public health issue, as with
tuberculosis, NTM is of emerging global interest and concern as
its pathogenic potential becomes more apparent and diseases
caused by NTM are increasingly prevalent. Incidence rates of
7.2 to 13.6 cases per 100 000 persons were recently reportedMicrobiol Infect 2015; 21: 236–241
nical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2014.10.018[1,2]. Rapidly growing mycobacteria (RGM) are important
causes of NTM infections, especially in Asia [3]. The proportion
of NTM contributed by RGM has increased more than 2-fold to
35% in 2001 vs. 14% for the period 1992 through 1996 [4].
Among the RGM, Mycobacterium abscessus, Mycobacterium for-
tuitum group and Mycobacterium chelonae are most common.
Clinical presentations of RGM disease are highly varied and
include infections of the respiratory tract (most common), skin
and soft tissue structures, bone and joint, lymphadenitis,
ophthalmic infections, otitis media and infection of the central
nervous system. In addition, infective complications caused by
RGM after surgical procedures and catheter use, as well as
disseminated infections, especially in immunocompromised
hosts, have been widely documented [5]. Treatment of serious
RGM infections is challenging; drug therapy typically involves a
multidrug regimen for a lengthy duration, is costly and isious Diseases. Published by Elsevier Ltd. All rights reserved
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rates are highly variable, particularly in pulmonary RGM in-
fections, with cure rates of only 30% to 50% [6].
The choice of antimicrobial therapy for RGM infections are
primarily based on in vitro antimicrobial susceptibility testing,
which in turn varies with the RGM species involved [7].
However, published reports on the epidemiology of NTM in-
fections to date are derived mainly from continents other than
Asia, and the possible geographical variation in the distribution
of this group of environmental bacteria suggest that their data
may not be directly relevant to the local context. Furthermore,
we have observed possible increase in antimicrobial resistance
among RGM species. We investigated the epidemiology and
in vitro antibiotic susceptibility proﬁles of RGM species isolated
in Singapore.MethodsThis observational cohort study was conducted involving RGM
isolates recovered from patients at three major hospitals in
Singapore: National University Health System (NUHS),
Singapore General Hospital (SGH) and Tan Tock Seng Hospital
(TTSH). The Central Tuberculosis Laboratory at SGH and the
NUHS mycobacteriology laboratory are involved in the iden-
tiﬁcation and antimicrobial susceptibility testing of all myco-
bacterial specimens in Singapore, and they provided the
database of clinical RGM isolates for this study. Institutional
review board approval was obtained at all study sites.
RGM isolates with antimicrobial susceptibility testing per-
formed between January 2006 and December 2011 were
included in this study. The types of clinical specimens from
which the isolate was recovered were noted. Specimen site was
classiﬁed as pulmonary if the RGM was isolated from sputum,
lung tissue biopsy sample, pleural ﬂuid or bronchoalveolar
lavage; as skin and soft tissue structure if it was a culture of
wound discharge or a biopsy specimen of a lesion involving skin,
subcutaneous tissue, muscle, synovium or bone [8]; as a
Tenckhoff catheter exit site if the specimen was of wound
discharge from an exit site without a positive peritoneal dialy-
sate (PD) culture; as PD peritonitis if RGM was isolated from
PD ﬂuid culture; and as lymphadenitis if a biopsy specimen or
swab of a lymph node yielded a RGM [9].
Minimum inhibitory concentrations (MICs) of all antibiotics
tested were recorded; only unique and nonduplicate isolates
from the ﬁrst culture of each patient were analysed. Linear
regression analyses were performed by SPSS Statistics software,
version 17.0 (IBM, Armonk, NY), to detect if there were any
signiﬁcant changes in antibiotic susceptibility over time. Results
with a p value of <0.05 were deemed statistically signiﬁcant.Clinical Microbiology and Infection © 2014 European Society of Clinical MicrobiologyRGM isolates at the Central Tuberculosis Laboratory in SGH
were identiﬁed by negative DNA probe (AccuProbe; Gen-Probe
Inc., San Diego, CA) and NAP (ρ-nitro-α-acetylamino-β-hy-
droxy-propiophenone) tests for Mycobacterium tuberculosis
complex. Clinically signiﬁcant isolates (determined by the
attending physician in accordance with the criteria set out by the
American Thoracic Society (ATS) [7]) were subsequently iden-
tiﬁed to species level by DNA reverse hybridization (INNO-
LiPA MYCOBACTERIA v2, Innogenetics NV, Ghent, Belgium)
and high-performance liquid chromatography. Discrepancies, if
any, were resolved through 16S ribosomal RNA sequencing
using primers 16S-27F (50-AGA GTT TGA TCM TGG CTC
AG-30) and 16S-907R (50-CCG TCA ATT CMT TTR AGT TT-
30). The NUHS mycobacteriology laboratory identiﬁed RGM to
species level by conventional biochemical methods (3-day aryl-
sulphatase reaction, nitrate reduction, mannitol, inositol, sorbi-
tol, and citrate utilization, tolerance to 5% NaCl, polymyxin
susceptibility and presence of pigmentation) [10]. Microbroth
dilution method was used in both institutions for antimicrobial
susceptibility testing and MICs were determined and interpreted
according to the guidelines established by the Clinical and Lab-
oratory Standards Institute (CLSI) [11]. Antibiotics tested
included amikacin, cefoxitin, clarithromycin, ciproﬂoxacin,
doxycycline, imipenem, linezolid, moxiﬂoxacin, trimethoprim-
sulfamethoxazole, tigecycline and tobramycin.ResultsA total of 427 RGM isolates from 392 patients were included in
this study. The rate of positive RGM cultures requiring species
identiﬁcation and antibiotic susceptibility testing was fairly sta-
ble at an average of 14.6 isolates per 100 000 population each
year [12]; there was also little variation in the proportion
contributed by each RGM species (Fig. 1). M. abscessus was the
most frequently recovered species (74%), followed by
M. fortuitum complex (22%) and M. chelonae (3%); Mycobacte-
rium mucogenicum was isolated in ﬁve cases and Mycobacterium
neoaurum in one.
Approximately two-thirds of all isolates (n = 277) were from
respiratory specimens; clinical samples from skin and soft tissue
structures were the next most common but accounted for only
42 of cases (10%). M. abscessus was the predominant species
identiﬁed across all sites, although M. fortuitum group was also
equally important in lymphadenitis (Table 1). Of 11 M. chelonae
isolates, six (55%) were recovered from the respiratory tract and
three (27%) from the bloodstream. M. mucogenicum (n = 3) and
M. neoaurum (n = 1) were largely implicated in central venous
catheter–related bloodstream infections; M. mucogenicum was
also identiﬁed from two respiratory specimens.and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 236–241
FIG. 1. Species distribution of rapidly growing mycobacteria by year from 2006 to 2011.
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M. abscessus and M. fortuitum group. Amikacin was active
against more than 90% of all RGM isolates, while tobramycin
had poor in vitro activity against most species, including
M. chelonae. Nearly all M. fortuitum group isolates were sus-
ceptible to ciproﬂoxacin, moxiﬂoxacin and trimethoprim-
sulfamethoxazole; in contrast, virtually all isolates of
M. abscessus and M. chelonae were resistant to these antibiotics
(Fig. 2). None of the isolates resistant to ciproﬂoxacin retained
susceptibility to moxiﬂoxacin; similarly, isolates that were
susceptible to ciproﬂoxacin were also susceptible to moxi-
ﬂoxacin. More than 95% of M. abscessus and M. chelonae iso-
lates were susceptible to clarithromycin, vs. 20% against
M. fortuitum group. Activities of cefoxitin and imipenem were
moderate against M. abscessus, M. chelonae and M. fortuitum
group; further analysis revealed that 86% of cefoxitin-resistant
M. fortuitum group but only 12.5% of cefoxitin-resistant
M. abscessus isolates retained at least intermediate suscepti-
bility towards imipenem.TABLE 1. Distribution of RGM species by site, regardless of
clinical relevance
Specimen site
No. (%) of isolates for:
Mycobacterium
abscessus
Mycobacterium
fortuitum group
Pulmonary (n = 269) 210 (76) 59 (21)
Skin and soft tissue structure (n = 41) 30 (71) 11 (26)
Blood (n = 33) 26 (65) 7 (18)
PD (n = 25) 21 (84) 4 (16)
Tenckhoff catheter exit site (n = 11) 10 1
PD peritonitis (n = 14) 11 3
Lymph node (n = 11) 5 (45) 6 (55)
Eye (n = 9) 9 (100) 0 (0)
Other (n = 22)a 13 (59) 9 (41)
RGM, rapidly growing mycobacterium; PD, peritoneal dialysis.
aOther sites of infection included brain, ear, gastrointestinal tract, liver and urinary
tract.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectOnly two-ﬁfths of M. fortuitum group and M. mucogenicum
isolates remained susceptible to doxycycline. On the other
hand, tigecycline displayed excellent in vitro activity against all
RGM isolates, with MIC90 not exceeding 0.5 μg/mL. On the
basis of the susceptibility breakpoint of MIC 8 μg/mL, linezolid
was active against 85% of M. fortuitum group isolates but
exhibited activity against only 42% and 33% of M. abscessus and
M. chelonae isolates, respectively.
Decrease in susceptibility of M. abscessus to linezolid by 8.8%
per year (68% in 2006 to 24% in 2011) (R2 = 0.948, p 0.001)
was observed. M. fortuitum group displayed increasing resis-
tance to imipenem at a rate of approximately 9.5% per year
(67% in 2006 to 7% in 2011) (R2 = 0.761, p 0.023) as well as to
clarithromycin at 4.7% per year (29% in 2006 to 7% in 2011)
(R2 = 0.719, p 0.033) (Fig. 3). Interestingly, a slight improvement
in susceptibility of M. abscessus to clarithromycin by 1.9% per
year (93% in 2006 to 98% in 2011) (R2 = 0.745, p 0.027) was
noted. No other secular trends in variation of antimicrobial
susceptibility were found.DiscussionTeo and Lo [13] reported the ﬁrst case series of 23 NTM in-
fections in Singapore in 1992, which was limited to pulmonary
manifestations but included slow-growing mycobacteria from
1976 to 1988. Our present study, involving RGM species alone,
identiﬁed a total of 392 cases over 6 years. Furthermore, we
identiﬁed M. abscessus to be the most important RGM in our
setting across all specimen sites; M. fortuitum group that was
reported to be the most common RGM species in the earlier
study was implicated in only 22% of our cases. This ﬁnding is
consistent with reports from Taiwan [8,14,15] and Japan [16],
and it underscores the importance of M. abscessus in theious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 236–241
TABLE 2. In vitro antimicrobial susceptibilities of RGM isolates
RGM species and antimicrobial agent (no. of isolates tested)
No. (%) of isolates: MIC (μg/mL)
Susceptible Intermediate Resistant Range 50% 90%
Mycobacterium abscessus
Amikacin (313) 282 (90) 28 (9) 3 (1) 0.5 to >128 16 16
Cefoxitin (300) 12 (4) 280 (93) 8 (3) 4 to >128 32 64
Clarithromycin (313) 299 (96) 3 (1) 11 (3) 0.06 to >16 0.25 1
Ciproﬂoxacin (312) 3 (1) 16 (5) 293 (94) 0.12 to >4 >4 >4
Doxycycline (292) 4 (1) 13 (5) 275 (94) 0.12 to >32 >32 >32
Imipenem (256) 4 (2) 202 (78) 50 (20) 4 to >64 16 >64
Linezolid (306) 127 (42) 128 (42) 50 (16) 0.5 to >64 16 32
Moxiﬂoxacin (124) 4 (3) 5 (4) 115 (93) 0.25 to >8 >8 >8
TMP/SMX (101) 6 (6) — 95 (94) 1/9 to >8/152 >8/152 >8/152
Tobramycin (288) 2 (1) 4 (1) 282 (98) 1 to >32 16 >32
Mycobacterium fortuitum group
Amikacin (94) 89 (95) 2 (2) 3(3) 0.5 to >128 1 16
Cefoxitin (87) 5 (6) 75 (86) 7 (8) 16 to >128 64 64
Clarithromycin (94) 19 (20) 31 (33) 44 (47) 0.12 to >16 4 >16
Ciproﬂoxacin (92) 85 (92) 4 (5) 3 (3) 0.12 to >4 0.12 1
Doxycycline (80) 32 (40) 4 (5) 44 (55) 0.12 to >32 16 >32
Imipenem (85) 25 (29) 57 (67) 3 (4) 1 to 32 8 16
Linezolid (87) 74 (85) 7 (8) 6 (7) 1 to >64 8 16
Moxiﬂoxacin (40) 40 (100) 0 0 0.25 to 0.5 0.25 0.25
TMP/SMX (35) 34 (97) — 1 (3) 0.25/4.75 to >8/152 0.5/9.5 2/38
Tobramycin (79) 4 (5) 2 (3) 73 (92) 1 to >32 16 >32
RGM, rapidly growing mycobacterium; TMP/SMX, trimethoprim-sulfamethoxazole.
CMI Tang et al. Mycobacteria in Singapore 239epidemiology of RGM infections in Asia. Unfortunately,
M. abscessus is resistant to many currently available antibiotics,
with amikacin and clarithromycin as the only two agents with
reliable in vitro activity.
Indeed, amikacin was the only antibiotic that retained activity
against all RGM species. On the other hand, tobramycin had
poor activity against most isolates. The CLSI [11] and ATS [7]
guidelines have advocated tobramycin as the preferredFIG. 2. Antimicrobial susceptibilities of Mycobacterium abscessus and Mycoba
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiologyaminoglycoside for M. chelonae infections as a result of its
previously demonstrated superior in vitro activity. However,
our analyses revealed that only 2 (18%) of 11 M. chelonae iso-
lates were susceptible to tobramycin, whereas amikacin was
active against 86% of them. The recent studies by Fernandez-
Roblas et al. [17] and Shen et al. [18] also reported high sus-
ceptibility rates of M. chelonae to amikacin, although notably
more than 80% of their isolates remained susceptible tocterium fortuitum group.
and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 236–241
FIG. 3. Secular trend of antimicrobial susceptibilities of (a) linezolid against Mycobacterium abscessus; (b) imipenem against Mycobacterium fortuitum
group; and (c) clarithromycin against M. fortuitum group.
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study precluded deﬁnitive conclusions; nonetheless, the
observation that few isolates were tobramycin susceptible,
coupled with the almost nonexistent use of this aminoglycoside
in clinical practice locally, highlighted the need to review the
value of routine testing of tobramycin activity against
M. chelonae (and other RGM) species in our local setting.
Linezolid was one of several newer agents reported to
possess antimycobacterial activity. Although mycobacterial
resistance to linezolid generally remains a rare occurrence,
cases of linezolid-resistant M. tuberculosis complex were re-
ported [19]. The molecular basis of linezolid resistance has yet
to be fully elucidated but involved mutations in genes encoding
for 23S rRNA and ribosomal proteins [20], as well as the
presence of efﬂux pumps [21]. M. abscessus was found to be the
least susceptible among common RGM species in our study,
and its increasing resistance to linezolid over time is of concern.
Although the reason for this observed trend is unclear, this
phenomenon is unlikely to be explained by variations in labo-
ratory practices (there were no changes in laboratoryClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectprotocols or susceptibility breakpoints) and/or sampling bias
(the number of isolates each year was comparable).
The increasing use of carbapenems in the context of growing
gram-negative resistance may have contributed to the observed
decreasing susceptibility of M. fortuitum group to imipenem.
Nevertheless, the M. fortuitum group species remained highly
susceptible to multiple antibiotics such as the quinolones,
trimethoprim-sulfamethoxazole, linezolid and doxycycline, all of
which are available in oral formulations and provide an attrac-
tive regimen for outpatient therapy. Although M. fortuitum
group is known to be more resistant than M. abscessus to
clarithromycin, the MICs observed in our study were signiﬁ-
cantly higher, with less than 20% of our isolates inhibited by
clarithromycin at 2 μg/mL while Yang et al. [4] and Fernandez-
Roblas et al. [17] reported clarithromycin susceptibility in more
than half of their isolates.
A major shortfall of this study is the lack of data on antibiotic
use in the patient before recovery of the RGM isolate. Previous
drug exposure could have inﬂuenced susceptibility patterns by
exerting selective pressure for more resistant strains.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 236–241
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RGM species presented in this study remain applicable as a
broad guide to the choice of empiric antibiotic therapy. Further,
this study was dominated by M. abscessus species isolated from
respiratory specimens; continued study of less common RGM
species, such as M. mucogenicum and M. neoaurum, and of pa-
tients with extrapulmonary manifestations of RGM infection is
necessary to obtain a more reliable representation of their
antimicrobial susceptibility proﬁles.
In conclusion, in this novel report on the epidemiology and
antibiotic susceptibility of RGM species in Singapore, we
demonstrated that there was temporal variation in distribution
and antimicrobial susceptibility proﬁles of RGM. Antibiotic op-
tions for treatment of RGM infections are increasingly limited
and may be particularly challenging in our setting because we
observed generally higher MICs in our study cohort.Transparency DeclarationPart of this work was previously presented as a poster at
IDWeek 2012, San Diego, California, 17–21 October 2012. All
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